Market
Which regulatory body will first approve a treatment based on the new Alzheimer's molecule by end of 2025?
2
Resolution / Starting Odds
FDA (United States) • 25%
EMA (European Union) • 25%
PMDA (Japan) • 25%
Other • 25%
Official announcements from regulatory bodies such as FDA, EMA, or other national health agencies
Story
Scientists Discover Molecule to Restore Cognitive Function and Potentially Reverse Dementia in Early Alzheimer's Disease
Jan 26, 2025, 01:16 AM
Recent research has unveiled a promising molecule that may restore cognitive function in early Alzheimer's disease. This discovery could facilitate the development of drugs aimed at slowing or potentially reversing dementia, according to the authors of the study. Additional findings highlight the loss of signaling fidelity between astrocyte endfeet and adjacent cerebral arterioles in an amyloid mouse model of Alzheimer's. Other studies have focused on the unique cellular neighborhood of the murine leptomeninges-cortical brain interface, as well as misclassification in memory modification in the AppNL-G-F knock-in mouse model of Alzheimer's disease. These insights contribute to a deeper understanding of the disease's mechanisms and potential therapeutic targets.
View original story
Similar markets
China • 25%
European Union • 25%
United States • 25%
Other • 25%
No • 25%
Pending • 25%
Unclear • 25%
Yes • 25%
Yes • 50%
No • 50%
Other • 25%
European Central Bank • 25%
BaFin (Germany) • 25%
US SEC • 25%
1-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
Rejection • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Full Approval • 25%
Other • 25%
Therapeutic Goods Administration (TGA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
European Medicines Agency (EMA) • 25%
